Featured Studies

Researchers at the National Institutes of Health (NIH) Clinical Center are testing if spironolactone can be used to treat PAH. Spironolactone is a medication that can help with fluid retention, however it may also be beneficial to adults with PAH by controlling inflammation and improving blood vessel function in the lungs.

If you or someone you know is drinking too much, the National Institutes of Health (NIH) may be able to help. We conduct studies on how alcohol affects the body and are looking for new ways to treat alcohol problems. If you qualify, you can receive alcoholism treatment at no-cost while you participate in our research.

Researchers at the National Institutes of Health (NIH) are testing NX-2127, an oral drug that degrades a protein in cancer cells called Bruton's tyrosine kinase (BTK), instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate your immune T-cells to attack the cancer.

The National Institute of Neurological Disorders and Stroke at the National Institutes of Health Clinical Center is looking for individuals with severe epilepsy or individuals who have experienced persistent seizure activity that cannot be controlled with medication, to participate in this research study. The goal of this research study is to provide surgical treatment to control these types of seizures. Participation requires an inpatient stay of up to 4 weeks, plus 3 outpatient visits within 2 years after surgery.

Heart disease is the leading cause of death and disability in the United States. Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers at the National Institutes of Health (NIH) want to find out more about these potential benefits.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is conducting a pilot intervention study for patients diagnosed with idiopathic membranous nephropathy. The purpose of this study is to evaluate the safety and effectiveness of Rituximab plus Cyclosporine in the treatment of membranous nephropathy. There is no cost for study-related medications or tests received.